The importance of targeting proliferating and quiescent cells in CLL
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
Whole genome sequencing in CLL: challenges and benefits
Can BCR inhibitors be used to treat all CLL patients or only a subset?
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design